BrightPath Biotherapeutics Co., Ltd.
4594.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥1 | ¥0 | ¥5 | ¥15 |
| % Growth | 1,473.6% | -98.6% | -65.7% | – |
| Cost of Goods Sold | ¥0 | ¥0 | ¥2 | ¥3 |
| Gross Profit | ¥1 | -¥0 | ¥3 | ¥12 |
| % Margin | 97.2% | -473.6% | 64.1% | 78.5% |
| R&D Expenses | ¥888 | ¥0 | ¥1,168 | ¥1,136 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥1,162 | ¥1,155 | ¥285 | ¥317 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥888 | ¥0 | ¥17 | ¥35 |
| Operating Expenses | ¥1,162 | ¥1,155 | ¥1,470 | ¥1,488 |
| Operating Income | -¥1,161 | -¥1,155 | -¥1,467 | -¥1,476 |
| % Margin | -102,464.1% | -1,604,276.4% | -27,785.2% | -9,579.7% |
| Other Income/Exp. Net | ¥12 | -¥11 | -¥17 | -¥6 |
| Pre-Tax Income | -¥1,149 | -¥1,166 | -¥1,484 | -¥1,482 |
| Tax Expense | ¥2 | ¥2 | ¥2 | ¥2 |
| Net Income | -¥1,151 | -¥1,168 | -¥1,486 | -¥1,484 |
| % Margin | -101,601.9% | -1,622,336.1% | -28,137% | -9,632.6% |
| EPS | -14.12 | -18.21 | -24.9 | -28.55 |
| % Growth | 22.5% | 26.9% | 12.8% | – |
| EPS Diluted | -14.12 | -18.21 | -24.9 | -28.55 |
| Weighted Avg Shares Out | 82 | 64 | 60 | 52 |
| Weighted Avg Shares Out Dil | 82 | 64 | 60 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥1 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥1,161 | ¥0 | ¥17 | ¥35 |
| EBITDA | -¥1,149 | -¥1,166 | -¥1,467 | -¥1,446 |
| % Margin | -101,434.2% | -1,619,147.2% | -27,783.2% | -9,386.6% |